Ian James Stratford

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4895880/ian-james-stratford-publications-by-year.pdf
Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141 papers	6,996 citations	43 h-index	79 g-index
148 ext. papers	7,650 ext. citations	5.3 avg, IF	5.13 L-index

#	Paper	IF	Citations
141	Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. *British Journal of Cancer*, **2020**, 122, 62-71	8.7	10
140	Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2). *European Journal of Medicinal Chemistry*, **2019**, 182, 111649	6.8	5
139	Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1). *ChemBioChem*, **2019**, 20, 2841-2849	3.8	10
138	Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44. *Molecular Pharmaceutics* , **2019**, 16, 2481-2493	5.6	38
137	Binding and Internalization in Receptor-Targeted Carriers: The Complex Role of CD44 in the Uptake of Hyaluronic Acid-Based Nanoparticles (siRNA Delivery). *Advanced Healthcare Materials*, **2019**, 8, e1901182	10.1	18
136	Evaluation of analogues of furan-amidines as inhibitors of NQO2. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1292-1297	2.9	12
135	Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. *Scientific Reports*, **2018**, 8, 16804	4.9	21
134	Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands. *Cancer Letters*, **2017**, 403, 98-107	9.9	37
133	Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery. *Molecular Pharmaceutics*, **2017**, 14, 2422-2436	5.6	88
132	The CD44-Mediated Uptake of Hyaluronic Acid-Based Carriers in Macrophages. *Advanced Healthcare Materials*, **2017**, 6, 1601012	10.1	70
131	Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. *BMC Clinical Pathology*, **2017**, 17, 27	3	23
130	Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. *Clinical Endocrinology*, **2017**, 87, 557-565	3.4	6
129	Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. *EMBO Molecular Medicine*, **2017**, 9, 1646-1659	12	11
128	Clinical development of new drug-radiotherapy combinations. *Nature Reviews Clinical Oncology*, **2016**, 13, 627-42	19.4	162
127	Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria. *European Journal of Medicinal Chemistry*, **2016**, 111, 33-45	6.8	19
126	Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. *Oncotarget*, **2016**, 7, 17035-46	3.3	18
125	Synthesis of hybrid natural product analogues with anti-tumour properties. *Tetrahedron*, **2016**, 72, 5433-5443	2.4	1

124	Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase. *Oncology Reports*, **2016**, 35, 1925-32	3.5	5
123	The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties. *FEBS Letters*, **2014**, 588, 1666-72	3.8	23
122	Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. *Molecular Cancer Therapeutics*, **2014**, 13, 2805-16	6.1	91
121	A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. *International Journal of Cancer*, **2014**, 135, 820-9	7.5	30
120	Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. *Cancer Research*, **2014**, 74, 5458-68	10.1	704
119	Serendipitous Discovery of a Cascade Approach to Perhydrodibenzofuranones Related to the Natural Product Incarviditone. *Synlett*, **2014**, 25, 1263-1266	2.2	3
118	Investigation of radiosensitivity gene signatures in cancer cell lines. *PLoS ONE*, **2014**, 9, e86329	3.7	34
117	A synthetic approach to novel carvotacetone and antheminone analogues with anti-tumour activity. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5066-9	2.9	2
116	Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. *Blood*, **2013**, 121, 251-9	2.2	109
115	Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer. *International Journal of Oncology*, **2013**, 42, 1961-72	4.4	20
114	Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2013**, 28, 360-9	5.6	72
113	In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-B signaling. *Molecular Cancer Therapeutics*, **2012**, 11, 194-203	6.1	17
112	Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects. *Biochemical Pharmacology*, **2011**, 81, 355-63	6	39
111	Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones. *Journal of Medicinal Chemistry*, **2011**, 54, 6597-611	8.3	12
110	Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. *Molecular Cancer Therapeutics*, **2011**, 10, 1949-58	6.1	140
109	Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice. *PLoS ONE*, **2010**, 5, e8584	3.7	153
108	Testing for hypoxia in forearm skin of patients with systemic sclerosis, assessed by pimonidazole. *Journal of Rheumatology*, **2010**, 37, 1968-9	4.1	2
107	Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. *Endocrine-Related Cancer*, **2010**, 17, 203-13	5.7	21

106	Spectrophotometric analysis of nucleic acids: oxygenation-dependent hyperchromism of DNA. *Analytical and Bioanalytical Chemistry*, **2010**, 396, 2331-9	4.4	11
105	Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells. *Biochemical Pharmacology*, **2010**, 80, 977-81	6	24
104	The synthesis of 2-oxyalkyl-cyclohex-2-enones, related to the bioactive natural products COTC and antheminone A, which possess anti-tumour properties. *Tetrahedron*, **2010**, 66, 9049-9060	2.4	14
103	Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 696-706	3.4	18
102	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7331-6	2.9	8
101	The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. *Clinical Cancer Research*, **2009**, 15, 6619-29	12.9	42
100	In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. *Molecular Cancer Therapeutics*, **2009**, 8, 3266-75	6.1	32
99	Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). *Molecular Cancer Therapeutics*, **2009**, 8, 1261-9	6.1	19
98	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). *Journal of Medicinal Chemistry*, **2009**, 52, 7142-56	8.3	70
97	The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells. *Radiation Research*, **2009**, 171, 572-80	3.1	12
96	iNOS as a therapeutic target for treatment of human tumors. *Nitric Oxide - Biology and Chemistry*, **2008**, 19, 217-24	5	65
95	Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved. *Toxicology in Vitro*, **2008**, 22, 582-8	3.6	21
94	Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). *Molecular Pharmacology*, **2008** , 74, 1657-65	4.3	30
93	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. *Journal of Endocrinology*, **2008**, 198, 499-509	4.7	55
92	Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. *European Journal of Medicinal Chemistry*, **2008**, 43, 1248-60	6.8	15
91	(−)-Quinic acid: a versatile precursor for the synthesis of analogues of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) which possess anti-tumour properties. *Tetrahedron Letters*, **2008**, 49, 2410-2413	2	13
90	Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase. *Journal of Pharmacy and Pharmacology*, **2007**, 59, 537-47	4.8	19
89	Analogues of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor properties. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 553-7	2.9	18

88	Arene cis-dihydrodiols: useful precursors for the preparation of analogues of the anti-tumour agent, 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC). *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5974-7	2.9	14
87	Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 84-90	4	67
86	Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. *Journal of Medicinal Chemistry*, **2007**, 50, 6316-25	8.3	56
85	Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. *Molecular Cancer Therapeutics*, **2007**, 6, 599-606	6.1	50
84	Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system. *Molecular Cancer Therapeutics*, **2007**, 6, 3122-30	6.1	34
83	Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. *Journal of Biomolecular Techniques*, **2007**, 18, 120-3	1.1	52
82	Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. *Molecular Pharmacology*, **2006**, 69, 411-8	4.3	104
81	In silico identification and biochemical characterization of novel inhibitors of NQO1. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 6246-54	2.9	29
80	Metabolic profiling of hypoxia-inducible factor-1□deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy. *Metabolomics*, **2006**, 1, 293-303	4.7	14
79	Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. *Radiotherapy and Oncology*, **2005**, 75, 89-98	5.3	114
78	Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. *Journal of Medicinal Chemistry*, **2005**, 48, 392-402	8.3	42
77	Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 213-22	4	18
76	Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression. *Journal of Cellular Biochemistry*, **2005**, 94, 1148-62	4.7	18
75	The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway. *Cancer Research*, **2005**, 65, 4147-52	10.1	43
74	Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. *Clinical Cancer Research*, **2005**, 11, 4212-6	12.9	19
73	Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia?. *Advances in Experimental Medicine and Biology*, **2005**, 566, 285-94	3.6	18
72	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. *Journal of the National Cancer Institute*, **2004**, 96, 56-67	9.7	399
71	ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. *Clinical Cancer Research*, **2004**, 10, 8587-93	12.9	129

70	Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. *Molecular and Cellular Biology*, **2004**, 24, 2875-89	4.8	317
69	Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. *Cancer Research*, **2004**, 64, 1396-402	10.1	75
68	Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. *Clinical Cancer Research*, **2004**, 10, 8405-12	12.9	112
67	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. *Journal of Clinical Investigation*, **2004**, 114, 1800-1811	15.9	131
66	Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. *Biochemical Pharmacology*, **2004**, 68, 2107-16	6	37
65	Hypoxia in tumors: molecular targets for anti-cancer therapeutics. *Advances in Enzyme Regulation*, **2004**, 44, 93-108		17
64	The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 376-85	4	19
63	Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5247-50	2.9	16
62	A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. *Journal of Medicinal Chemistry*, **2004**, 47, 5683-9	8.3	48
61	Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. *Radiotherapy and Oncology*, **2004**, 70, 91-7	5.3	24
60	Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. *Molecular Pharmacology*, **2003**, 63, 1248-55	4.3	27
59	Combining bioreductive drugs and radiation for the treatment of solid tumors. *Seminars in Radiation Oncology*, **2003**, 13, 42-52	5.5	25
58	3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro. *Biochemical Pharmacology*, **2003**, 66, 1199-206	6	16
57	GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. *International Journal of Cancer*, **2003**, 104, 85-91	7.5	191
56	Time-dependence and preliminary SAR studies in inhibition of nitric oxide synthase isoforms by homologues of thiocitrulline. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 3679-80	2.9	8
55	Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 4189-206	3.4	34
54	Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. *Journal of Medicinal Chemistry*, **2003**, 46, 207-9	8.3	43
53	Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. *American Surgeon*, **2003**, 69, 24-7	0.8	5

52	Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. *Molecular Cancer Therapeutics*, **2003**, 2, 901-9	6.1	23
51	Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 525-30	3.4	24
50	A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. *Oncogene*, **2002**, 21, 282-90	9.2	71
49	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. *Journal of Urology*, **2002**, 167, 1482-1486	2.5	18
48	Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. *Current Pharmaceutical Design*, **2002**, 8, 1319-33	3.3	12
47	Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. *Cancer Research*, **2002**, 62, 688-95	10.1	75
46	Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. *Cancer Research*, **2002**, 62, 2962-70	10.1	37
45	Bioreductive and gene therapy approaches to hypoxic diseases. *Advanced Drug Delivery Reviews*, **2001**, 53, 217-28	18.5	39
44	Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations. *Breast Cancer Research*, **2001**, 3, 328-31	8.3	44
43	The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. *Biochemical Pharmacology*, **2000**, 59, 993-6	6	36
42	Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. *Cancer Chemotherapy and Pharmacology*, **2000**, 45, 111-9	3.5	17
41	Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. *Radiotherapy and Oncology*, **2000**, 57, 53-9	5.3	190
40	Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1787-96	3.4	20
39	Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. *Journal of Medicinal Chemistry*, **1999**, 42, 4071-80	8.3	58
38	Bioreductive drugs: selectivity towards hypoxic tissue. *Expert Opinion on Therapeutic Patents*, **1999**, 9, 1371-1380	6.8	8
37	Synthesis and cytotoxic activity of thiazolyl indolequinones. *Anti-Cancer Drugs*, **1999**, 10, 577-89	2.4	3
36	S-2-amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS). *Bioorganic and Medicinal Chemistry*, **1998**, 6, 2139-49	3.4	15
35	Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. *Journal of Medicinal Chemistry*, **1998**, 41, 2720-31	8.3	61

34	Targeting gene expression to hypoxic tumor cells. *Nature Medicine*, **1997**, 3, 515-20	50.5	332
33	2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. *Journal of Medicinal Chemistry*, **1997**, 40, 2335-46	8.3	49
32	Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. *Biochemical Pharmacology*, **1996**, 51, 829-37	6	23
31	A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. *Acta Oncologica*, **1996**, 35, 989-94	3.2	5
30	Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. *Breast Cancer Research and Treatment*, **1996**, 38, 97-108	4.4	46
29	Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo. *Anti-Cancer Drugs*, **1995**, 6, 259-69	2.4	12
28	Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 277-83	4	21
27	31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589C. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 285-8	4	4
26	Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 339-44	4	3
25	The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 369-72	4	22
24	Combination of photodynamic therapy (PDT) and melphalan in experimental tumors. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 463-6	4	1
23	Bioreductive drugs for cancer therapy: the search for tumor specificity. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 231-8	4	72
22	Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT). *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 329-32	4	5
21	Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity. *International Journal of*	4	6
20	Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 443-7	4	16
19	Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones. *Journal of Medicinal Chemistry*, **1994**, 37, 3834-43	8.3	36
18	Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. *Biochemical Pharmacology*, **1994**, 48, 277-85	6	41
17	Potential antitumour mitosenes: relationship between in vitro DNA interstrand cross-link formation and DNA damage in Escherichia coli K-12 strains. *Biochemical Pharmacology*, **1994**, 48, 1371-7	6	13

16	Cyclopropamitosenes. *Anti-Cancer Drugs*, **1994**, 5, 367-372	2.4	17
15	2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives. *Journal of Medicinal Chemistry*, **1992**, 35, 3573-8	8.3	15
14	Metal complexes as radiosensitizers: Cobalt(II), copper(II), rhodium(II) and platinum(II) complexes of 3-(1-imidazoyl)propionic acid and some nitro-substituted derivatives, and the crystal structure and radiosensitizer activity of [CuL2(H2O)]2 □2H2O, where LH = 3-[1-(4-nitroimidazoyl)]propionic acid. *Polyhedron*, **1992**, 11, 2507-2515	2.7	10
13	Magnetic resonance spectroscopy studies on experimental murine and human tumors: comparison of changes in phosphorus metabolism with induced changes in vascular volume. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 467-71	4	10
12	The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 473-6	4	25
11	Metal complexes of ligands containing intercalating units. Synthesis of nickel(II), copper(II), rhodium(II), and platinum(II) complexes with diamine-substituted acridines and quinolines, and with mitonafide [N-(2,2-dimethylaminoethyl)-3-nitro-1, 8-naphthalimide] and related ligands. *Transition Metal Chemistry*, **1991**, 16, 223-229	2.1	6
10	Dual-Function 2-Nitroimidazoles as Hypoxic Cell Radiosensitizers and Bioreductive Cytotoxins: In Vivo Evaluation in KHT Murine Sarcomas. *Radiation Research*, **1990**, 124, S38	3.1	23
9	Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. *Journal of Medicinal Chemistry*, **1990**, 33, 2603-10	8.3	76
8	The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. *International Journal of Radiation Oncology Biology Physics*, **1989**, 16, 973-6	4	71
7	Nitro derivatives of bi- and tri-cyclic heterocycles as potential radio-sensitizers. *European Journal of Medicinal Chemistry*, **1989**, 24, 511-516	6.8	3
6	Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy. *International Journal of Radiation Oncology Biology Physics*, **1986**, 12, 1299-302	4	46
5	Synthesis, characterisation and radiosensitizing properties of some nitroimidazole adducts of rhodium(II) carboxylates; X-ray structure of {Rh(CH3CO2)2-[1-(2-hydroxy-3-methoxypropyl)-2-methyl-5-nitroimidazole])2}. *Inorganica Chimica Acta*, **1986**, 125, 143-149	2.7	17
4	RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. *Biochemical Pharmacology*, **1986**, 35, 105-9	6	100
3	Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers. *International Journal of Radiation Oncology Biology Physics*, **1982**, 8, 391-8	4	38
2	Preincubation with electron affinic radiosensitizers followed by hyperthermia or X rays. *International Journal of Radiation Oncology Biology Physics*, **1982**, 8, 767-70	4	2
1	Mammalian cell toxicity of nitro compounds : dependence upon reduction potential. *Biochemical and Biophysical Research Communications*, **1976**, 72, 824-9	3.4	97